Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial.
Clinical trial NCT07335952 · COMPLETED
Trial details
- NCT number
- NCT07335952
- Sponsor
- Peking University People's Hospital
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-09-02
- Primary completion
- 2025-10-09
- Enrollment
- 179
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.